Mirtazapin Hexal (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Hexal, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as a tablet for oral use. It treats major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine is used to treat depressive disorders by modulating noradrenergic and serotonergic pathways.

- Major depressive disorder: alleviates depressive symptoms and improves mood in adult patients.

Mirtazapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Hepatic dysfunction or jaundice - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Suicidal thoughts or behavior, especially early in treatment - Serotonin syndrome when combined with other serotonergic agents

When prescribing Mirtazapine, clinicians should consider several precautionary measures to ensure safe use.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor weight: patients may experience significant weight gain. - Screen for suicidal ideation: particularly during the first weeks of treatment. - Use caution in elderly: increased risk of sedation, falls, and orthostatic hypotension. - Avoid abrupt discontinuation: taper the dose under medical supervision to reduce withdrawal symptoms. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Mirtazapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; avoid concurrent use. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential for serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may modestly raise drug concentrations. - Alcohol: can enhance central nervous system depression. - Other CNS depressants (e.g., benzodiazepines, antihistamines): additive sedative effects.